A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma



Pratt, Guy, Yap, Christina, Oldreive, Ceri, Slade, Daniel, Bishop, Rebecca, Griffiths, Mike, Dyer, Martin JS, Fegan, Chris, Oscier, David, Pettitt, Andrew
et al (show 9 more authors) (2018) A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma. BRITISH JOURNAL OF HAEMATOLOGY, 182 (3). pp. 429-433.

[thumbnail of PICLLe BJH letter-April 2017.docx] Text
PICLLe BJH letter-April 2017.docx - Author Accepted Manuscript

Download (62kB)
[thumbnail of Letter_Table_1_25_01_2017.pdf] Text
Letter_Table_1_25_01_2017.pdf - Author Accepted Manuscript

Download (12kB)
[thumbnail of Letter_Table_2_25_01_2017.pdf] Text
Letter_Table_2_25_01_2017.pdf - Author Accepted Manuscript

Download (24kB)
Item Type: Article
Uncontrolled Keywords: chronic lymphocytic leukaemia, mantle cell lymphoma, DNA damage, olaparib
Depositing User: Symplectic Admin
Date Deposited: 17 Sep 2018 10:45
Last Modified: 19 Jan 2023 01:18
DOI: 10.1111/bjh.14793
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3026120